Phase III Study to Assess Long-Term Safety of Tozorakimab in Adults with COPD and History of Exacerbations

What this Trial Is About

Researchers are evaluating the long-term safety of two different dose regimens of tozorakimab in people with Chronic Obstructive Pulmonary Disease COPD who have a history of exacerbations. This Phase III, multicenter, open-label extension study includes participants who have already completed earlier related studies. The aim is to better understand how these treatments perform over an extended period. Participants receive tozorakimab through subcutaneous injections using pre-filled syringes. The study compares two dosing regimens, with participants continuing treatment from predecessor studies such as MIRANDA, TITANIA, or PROSPERO. This chronic dosing extension allows researchers to observe safety over a long timeframe. During the study, participants will have regular assessments to monitor adverse events and overall health status for up to 2 to 3 years. Researchers will collect safety data, including any side effects, to evaluate tolerability. Participants must provide informed consent and follow study procedures while being monitored closely throughout the trial period, which lasts until late 2028.

Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations